CRISPR gene therapy trial gets approval from the NIH

Sara Reardon, Nature News, 22 June 2016

An NIH advisory board has approved the use of CRISPR gene editing in a small scale cancer therapy trial.  Eighteen patients with various cancers will have their T cells removed and edited using CRISPR before reintroduction.  The T-cells will be edited to detect and destroy cancer cells effectively using the patients own immune system to treat cancer.  This will not be the first use of edited T-cells to target disease.  Previously zinc finger proteins had been used to edit T-cells in HIV patients and TALENS have been used to edit T-cells in cancer therapies.  The use of CRISPR technology is an important step forward as the CRISPR/Cas system could be easily adapted to treat a variety of diseases.

Author: Advanced Analytical

Advanced Analytical Technologies, Inc. (AATI) simplifies complex genomics workflows to accelerate research and discovery in pharmaceuticals, life science, biofuels, biotechnology and healthcare.

Leave a Reply